GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (NAS:NTBL) » Definitions » LT-Debt-to-Total-Asset

Notable Labs (Notable Labs) LT-Debt-to-Total-Asset : 0.08 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Notable Labs LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Notable Labs's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.08.

Notable Labs's long-term debt to total assets ratio declined from Dec. 2021 (0.15) to Dec. 2023 (0.08). It may suggest that Notable Labs is progressively becoming less dependent on debt to grow their business.

Notable Labs LT-Debt-to-Total-Asset Historical Data

The historical data trend for Notable Labs's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Notable Labs LT-Debt-to-Total-Asset Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
0.15 - 0.08

Notable Labs Semi-Annual Data
Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset 0.15 - 0.08

Notable Labs LT-Debt-to-Total-Asset Calculation

Notable Labs's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=1.526/19.541
=0.08

Notable Labs's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=1.526/19.541
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Notable Labs  (NAS:NTBL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Notable Labs LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Notable Labs's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Notable Labs (Notable Labs) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (NAS:NTBL) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
NLSP ACST AGE CRBP NBIO CLRB AIM PLUR BIXT SNSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
320 Hatch Drive, Foster City, CA, USA, 94404
Website
https://notablelabs.com
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic.